WOLVERINE
“Wolverine” is the community nickname for combining BPC-157 and TB-500 around injury recovery, tissue repair and inflammation. Each component has its own research story. The combination itself is a different evidence question—and evidence from either ingredient cannot simply be added together and called evidence for the blend.
Wolverine combines BPC-157 and TB-500 in an attempt to bring together two different tissue-repair signals, which is why the blend has become so prominent in recovery communities.
Combination evidence is missing.
The rationale comes from two separate biological stories. Direct evidence that the combination improves human recovery is not established.
A community-created recovery stack—not a single drug.
Wolverine is an informal name for using BPC-157 and TB-500 together. It is not a clinical term and does not describe an FDA-approved combination product.
The pairing is now sufficiently prominent that it appears in contemporary reporting and FDA adverse-event review materials. But popularity answers a different question from efficacy: it tells us what people are trying, not whether the combination has been shown to work.
The rationale is complementary repair biology.
This is where the evidence becomes unusually thin.
We did not identify a controlled human trial testing BPC-157 + TB-500 as a combination therapy.
FDA's 2026 TB-500 review reported that its FAERS search found two cases involving “blended TB-500 and BPC-157,” but those reports did not contain safety assessments. FDA also stated that it had not identified clinical studies or human exposure data for TB-500 itself via any route.
That makes Wolverine a useful example of why the Index needs a separate Blend category: a combination can become culturally established long before the combination itself becomes scientifically established.
Even the two ingredients do not have equivalent evidence.
BPC-157: the literature is dominated by animal and mechanistic research. A 2025 human IV pilot included only two participants and assessed short-term safety—not injury-repair efficacy.
TB-500: this is the seven-amino-acid N-acetyl-LKKTETQ fragment of thymosin beta-4. Human trials frequently cited in peptide discussions have studied full-length thymosin beta-4 rather than TB-500, and those molecules should not be treated as clinically interchangeable.
This is exactly why Community Signal exists.
Wolverine has become one of the recognizable recovery combinations in peptide culture, particularly around musculoskeletal injuries, training recovery and post-injury experimentation.
That level of adoption is information. It can reveal where people believe they are seeing repeatable patterns and can help define questions worth studying. It does not tell us the size of an effect, whether the effect exceeds placebo or natural recovery, or whether the combination is safer or more effective than either component alone.
Where combination logic becomes combination mythology.
VERY WIDE
Wolverine has unusually strong community recognition relative to its direct evidence. The combination is built on plausible but separately derived repair biology; whether combining the compounds improves meaningful human recovery outcomes remains unanswered.
Combination uncertainty compounds component uncertainty.
FDA's current compounding safety information identifies potential immunogenicity and peptide-impurity/API-characterization concerns for BPC-157 and TB-500. For TB-500, FDA says it has not identified human exposure data and lacks important safety information.
At its July 2026 Pharmacy Compounding Advisory Committee meeting, FDA reviewed BPC-157-related and TB-500-related bulk substances for possible inclusion on the 503A Bulks List. That process concerns compounding policy; it is not FDA approval of either substance or of the Wolverine combination.
What supports the profile.
| Evidence | Type | What it adds | What it cannot prove |
|---|---|---|---|
| 2025 · PMID 40131143 | BPC-157 human pilot; n=2 | Short-term IV safety observations in two participants. | Does not establish injury efficacy or combination efficacy. |
| FDA · 2026 BPC-157 review | Regulatory evidence review | Summarizes limited human data and current safety uncertainties. | Does not establish Wolverine efficacy. |
| FDA · 2026 TB-500 review | Regulatory evidence review | Distinguishes TB-500 from full-length thymosin beta-4 and reports no identified human exposure studies for TB-500. | Does not tell us whether the combination works. |
| FDA · July 2026 PCAC | 503A Bulks List review | Current federal compounding-policy context for both components. | Advisory review is not drug approval. |
Separate the blend from its ingredients.
BPC-157
Explore the preclinical repair story, limited human signal and very wide evidence gap.
TB-500
See why TB-500 must be distinguished from the human literature on full-length thymosin beta-4.
Recovery
Compare Wolverine with the broader recovery landscape and evidence hierarchy.